Eli Lilly (LLY) stock extended gains on Wednesday after the pharmaceutical behemoth announced a new direct-to-consumer (DTC) collaboration with CVS Health (CVS).
The press release said this team-up aims to improve patient access, affordability, and pharmacy support for Eli Lilly's blockbuster weight-loss treatments, Zepbound and Foundayo.